Ludlow Capital Initiates Coverage on China BioPharma's Influenza Vaccine Research.BOSTON -- Ludlow China, a research subsidiary of Ludlow Capital announced today that it has initiated Coverage of Techedge, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : TEDG), and their potential acquisition of China BioPharma. TechEdge has signed a Letter of Intent to acquire China BioPharma Limited, a Cayman Island company, which has the rights to have majority ownership to Tianyuan Bio-pharmaceuticals. Tianyuan Bio-pharmaceuticals currently has 4 vaccines in their portfolio covering such diseases as Ebola Hemorrhagic Fever Noun 1. Ebola hemorrhagic fever - a severe and often fatal disease in humans and nonhuman primates (monkeys and chimpanzees) caused by the Ebola virus; characterized by high fever and severe internal bleeding; can be spread from person to person; is largely limited to , and Influenza virus vaccine influenza virus vaccine n. A vaccine containing influenza virus, usually several strains of the virus, prepared in chick embryos and used to immunize against influenza. , inactive. With the H5N1 Avian avian /avi·an/ (a´ve-an) of or pertaining to birds. a·vi·an adj. Of, relating to, or characteristic of birds. Bird Flu bird flu: see influenza. bird flu or avian influenza viral respiratory disease, mainly of birds including poultry and waterbirds but also transmissible to humans. virus penetrating across the Northern Hemisphere, we feel the potential acquisition of vaccine producer China BioPharma, and their rights to Tianyuan Bio-pharmaceuticals may position the company as a leader in the viral and vaccine research and production sector. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. a company update released on March 27, 2006, the company realized $10 million in sales for fiscal year 2005, with a net profit of $1.5 million, unaudited. To view the Ludlow Capital's Profile for TechEdge, Inc., please visit: http://www.theasianinvestor.com/reports/tedg.htm. About Tianyuan Bio-pharmaceuticals Tianyuan Bio-pharmaceutical Co., Ltd., is one of the largest non-government owned vaccine manufactures in China. The company main products are vaccines for epidemic hemorrhagic fever epidemic hemorrhagic fever n. An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting. and influenza with high reputation and market-occupying rate. The vaccines for epidemic hemorrhagic fever and Influenza virus influenza virus n. Any of three viruses of the genus Influenzavirus designated type A, type B, and type C, that cause influenza and influenzalike infections. , and has been awarded the National New Product Prize and National Tech Progress Prize. The company plans to establish the production for 5 to 8 products of 3 major series in the aspects of bacterial, virus, and viral vaccines, having accomplished a batch of technical achievements with autonomous intellectual property, and formed its own core competitive force. For more information on their current vaccines visit www.ty-pharm.com Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. : This press release includes ``forward-looking statements'' within the meaning of the federal securities laws, commonly identified by such terms as ``believes,'' ``looking ahead,'' ``anticipates,'' ``estimates'' and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: Ludlow Capital has been compensated up to ten thousand shares free trading by a third party and fifty thousand restricted 144 shares by the company for twelve month research coverage on the company. Ludlow Capital is not a registered investment adviser or broker/dealer. Ludlow Capital makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion